RARA and acute promyelocytic leukemia: The type of the RARa-fusion partner is an essential determinant of response to ATRA, indicating the importance of molecular characterization of APL patients in determining the most appropriate treatment approach and additionally specifying targets for Minimal Residual Disease (MRD) monitoring 2.